this is from the EH report from April ‘23 - Earlier this year, Kaken released its 3Q’FY22 results, showing the company had generated ¥1.05 Trillion of sales year to date from Sofpironium Bromide, with guidance of ¥1.4 Trillion of sales for the full financial year 2022.
Ann: Trading Halt, page-107
-
- There are more pages in this discussion • 102 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.0¢ |
Change
-0.005(1.18%) |
Mkt cap ! $761.8M | |||
| Open | High | Low | Value | Volume |
| 43.0¢ | 44.5¢ | 41.5¢ | $2.435M | 5.697M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 819538 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 29052 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |